

DISCLAIMER: PLEASE READ AND REVIEW THE DISCLAIMERS SET FORTH IN THE ATTACHED SCHEDULE “A” CAREFULLY BEFORE REVIEWING THIS DOCUMENT. IF YOU ARE A CANADIAN INVESTOR PLEASE ALSO READ AND REVIEW THE ATTACHED SCHEDULE “B”.

INVESTMENT OPPORTUNITY PSYCHEDILITECH INC.

An Investment Opportunity into the Untapped, Emerging Psychedelic Market

Raising up to \$600,000 at \$0.10 per Share

Current Raise: USD \$600,000

Eligibility: Accredited Investors (within the meaning of applicable securities laws) only.

Company Overview

Psychedelitech Inc. (the “**Company**”) intends on developing a psychedelic discovery platform for early-stage investments. The Company’s product offerings are expected to be sourced through the establishment of one of the world’s leading Psychedelic summits, aimed at the innovation, investment and research side of psychedelic sciences.

Management targets to begin and operate the first Psychedelic Summit in Tel Aviv, Israel, Maryland, USA and Holland, Netherlands

Comparing the Medical Mushroom and Cannabis Markets

Management believes that the psychedelic industry is beginning to show signs of promising regulatory change, similar to that experienced by the cannabis industry.

The cannabis industry, which was at one time untouched and illegal, has grown into a massive industry through its medical boom as well as recreational legalization in Canada and other countries.

Although at different timelines and stages, Management believes that both industries' products are developing traction and increasing interest and acceptance by health professionals and consumers.

The health effects of psilocybin (the nootropic compound found within psychoactive fungi species), though unproven, are becoming more acceptable in jurisdictions including Canada, the USA and other countries, with deregulation happening now in Denver and California. Today, numerous molecules can be studied including Psilocybin, Ketamine, MDMA, and LSD

Many high-risk early investors in the medical cannabis industry were among the biggest winners in the quickly-expanding market. For example, between 2014 and 2017, the adult-use and medical cannabis industry grew from approximately \$4.6 Billion to \$8.5 Billion in revenue in the USA and Canada.

Key Management

Saul Kaye is the visionary founder of CannaTech and iCAN. iCAN was established in 2015 with the goal of destigmatizing cannabis globally and accelerating global cannabis innovation. Saul created one of the cannabis industry's premier global cannabis events and created deal flow nearing \$5 billion. Saul is a serial entrepreneur and founder of pharmacy-related businesses in Israel, Turkey, Australia, the USA, and India. Saul has extensive formulation knowledge and has successfully launched pharmaceutical and wellness brands in over 35 countries.

Ronnie Eshel has 20+ years of experience in regulation, clinical trials, medical devices, and manufacturing operations, including 15 years of experience in Life Sciences innovation. Ronnie has worked in Israeli start-ups where he led efforts in development, regulatory compliance, and operations. Ronnie has navigated the USA, European, Israeli and Australian regulatory agencies including the registration of manufacturing facilities in the USA, Central America, Israel and Australia to GMP levels, and led clinical trials in the USA, Europe and Israel, working with CROs all over the world.

Advisors

- Dr. Robin Ely MD
- Dr. Mark Braunstein MD
- Additional advisors in progress.

Anticipated Use of Proceeds

- Legal, Finance & Compliance: USD \$50,000
- Event 1: USD \$200,000
- G&A: USD \$200,000
- Clinical trial preparation: USD \$150,000

Proposed Financing Details

- Issue price: USD \$0.10 Per Share
- Pre-money valuation: USD \$1,500,000
- Shares outstanding: 15,000,000
- Total offering size: USD \$600,000

Latest closing date: Dec 31, 2019

BOOKS MAY CLOSE AT ANY TIME

SCHEDULE “A” – General Disclaimer

General: The information contained in this presentation has been prepared by Psychedelitech Inc. (the “Company”, “we”, “us”, or “our”) for information only. This presentation contains information pertaining to the business, operations and assets of the Company. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company, and (c) is not to be considered as a recommendation by the Company to purchase any securities of the Company. An investment in the securities of the Company is speculative and involves a number of risks that should be considered by a prospective investor. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information.

All information and data provided in this presentation is strictly private and confidential. No person is authorized to copy or re-distribute any materials in this presentation without the express permission of the Company. This presentation constitutes an “offering memorandum” under applicable Canadian securities laws (including pursuant to the *Securities Act* (Ontario) and OSC Rule 45-501 *Ontario Prospectus and Registration Exemptions*). If you are a Canadian purchaser, please see “Schedule “B” - *Statutory Rights of Rescission (for Canadians)*” at the end of this presentation for further information. Prospective investors should be aware that the purchase of any securities of the Company may have tax consequences both in Canada and the United States. As such, this presentation should not be construed as legal, financial or tax advice to any prospective investor, and each prospective investor should consult its own tax advisor concerning the investment described herein. This presentation may include market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although the Company believes it to be reliable, it has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements & Future Oriented Financial Information: Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions which would cause actual results or events to differ materially from those presently anticipated, including, but not limited to: the costs of compliance with and the risk of liability being imposed under the laws of the jurisdictions in which the Company operates, including environmental and health product regulations; negative changes in the political environment or in the regulation of the product offerings of the Company and the Company’s business in one or more jurisdictions, which may include jurisdictions such as the United States, Canada and Europe; negative shifts in public opinion and perception of the industry within which the Company operates; increasing competition in the industry within which the Company operates; risk that purchasers and researchers will not purchase the Company’s products; risks of product liability and other safety related liability as a result of usage of the Company’s product offerings; negative future research regarding safety and efficacy of the Company’s product offerings; risk of shortages of or price increases in key inputs, suppliers and skilled labor; and potential loss of any intellectual property rights. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward- looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results,

performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this document. Investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this document are based upon what management of the Company currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Forward-Looking Statements”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations.

If you are a Canadian investor, please read and review the attached Schedule “B”.